StoneX Maintains Buy on AbCellera Biologics, Raises Price Target to $15
Benzinga Newsdesk 47 minutes ago
Analyst RatingsNewsPrice Target
StoneX analyst Robert Wasserman maintains AbCellera Biologics (NASDAQ:ABCL) with a Buy and raises the price target from $11 to $15.
StoneX analyst Robert Wasserman maintains AbCellera Biologics (NASDAQ:ABCL) with a Buy and raises the price target from $11 to $15.